NCT01252888

Brief Summary

The purpose of this study is to assess efficacy and safety of two iStents for the reduction of intraocular pressure associated with primary open-angle glaucoma.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
39

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Dec 2010

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 1, 2010

Completed
Same day until next milestone

Study Start

First participant enrolled

December 1, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 3, 2010

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2016

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2016

Completed
Last Updated

September 7, 2022

Status Verified

December 1, 2017

Enrollment Period

5.6 years

First QC Date

December 1, 2010

Last Update Submit

September 2, 2022

Conditions

Keywords

Open angleGlaucomaSurgeryGlaucoma Open-AngleOcular HypertensionEye Diseases

Outcome Measures

Primary Outcomes (1)

  • mean diurnal IOP reduction of greater than or equal to 20% at Month 12 vs baseline

    12 months

Secondary Outcomes (1)

  • Mean diurnal IOP < 18 mmHg at month 12

    12 months

Study Arms (1)

Two iStent devices and medication

EXPERIMENTAL

Implantation of two iStents through small temporal clear corneal incision

Device: iStents

Interventions

iStentsDEVICE

Implantation of two iStents through a small temporal clear corneal incision

Two iStent devices and medication

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosed with primary open-angle glaucoma (POAG)
  • Subjects on two topical hypotensive medications

You may not qualify if:

  • Traumatic, uveitic, neovascular, or angle closure glaucoma
  • Fellow eye already enrolled

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

S.V. Malayna's Ophthalmology Centre

Yerevan, 375108, Armenia

Location

Related Publications (2)

  • Ahmed II, Katz LJ, Chang DF, Donnenfeld ED, Solomon KD, Voskanyan L, Samuelson TW. Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma. J Cataract Refract Surg. 2014 Aug;40(8):1295-300. doi: 10.1016/j.jcrs.2014.07.004.

    PMID: 25088627BACKGROUND
  • Chang DF, Donnenfeld ED, Katz LJ, Voskanyan L, Ahmed II, Samuelson TW, Giamporcaro JE, Hornbeak DM, Solomon KD. Efficacy of two trabecular micro-bypass stents combined with topical travoprost in open-angle glaucoma not controlled on two preoperative medications: 3-year follow-up. Clin Ophthalmol. 2017 Mar 15;11:523-528. doi: 10.2147/OPTH.S121041. eCollection 2017.

    PMID: 28352151BACKGROUND

MeSH Terms

Conditions

GlaucomaGlaucoma, Open-AngleOcular HypertensionEye Diseases

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 1, 2010

First Posted

December 3, 2010

Study Start

December 1, 2010

Primary Completion

July 1, 2016

Study Completion

December 1, 2016

Last Updated

September 7, 2022

Record last verified: 2017-12

Locations